美国胃肠病协会临床实践指南解读:胃黏膜肠上皮化生的管理(2019年)  

Interpretation of American Gastroenterological Association clinical practice guidelines on management of gastric intestinal metaplasia(2019 edition)

作　　者：玉珍[1] 戴芸[2] Yu Zhen;Dai Yun(Department of Gastroenterology,Tibet Autonomous Region People's Hospital,Lhasa 850000,China;Department of Gastroenterology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]西藏自治区人民医院消化内科,拉萨850000 [2]北京大学第一医院消化内科,100034

出　　处：《中华临床医师杂志（电子版）》2020年第3期166-169,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：胃癌在全球癌症相关性死亡率中排名第3位。胃黏膜肠上皮化生(GIM)为一种常见的癌前病变,与胃癌发生密切相关。根据循证医学的证据,2019年12月美国胃肠病协会(AGA)发布了针对GIM患者管理的临床实践指南。本文将就该指南中的主要推荐意见进行解读。Gastric cancer is the third leading cause of cancer death worldwide.Gastric intestinal metaplasia(GIM)represents the histologic step prior to the development of dysplasia and is routinely encountered in clinical practice,which has been associated with an increased risk for gastric cancer.Recently,the American Gastroenterological Association published evidence-based guidelines for management of patients with GIM incidentally detected on gastric biopsies.Herein,we mainly explain some controversial issues in such guidelines.

关 键 词：肠上皮化生 胃癌 监测 

分 类 号：R735.2[医药卫生—肿瘤]